This idea is particularly relevant considering the number of therapeutics currently in clinical trials for AMD that disrupt the complement cascade by either inhibiting complement components (i.e., C5, C3) or increasing molecules that inhibit the complement cascade (CFH, CD59) [61]. This evidence concerns the gene C5 and age-related macular degeneration.